Log in
The spin-out company, Degrasense, has developed and protected intellectual property of technology capable of quantifying specific proteolytic enzymes through changes in electrochemical responses (impedance) at electrodes due to the enzymatic degradation of polymer coatings. The company has detected several specific proteases that are relevant to the monitoring and treatment of a number of conditions including: periodontal disease, multiple sclerosis, haemophilia and hypertension. The technology is currently being validated in a clinical trial as a point of care sensor for the detection of active periodontal disease. Point-of-care sensors provide immediate, low-cost test results in non-laboratory settings, offering a more patient-centred approach to healthcare and earlier detection of disease.
Fundus autofluorescence imaging has transformed understanding of retinal disease and brought enormous benefit to millions of patients world-wide. By visualising what is predominantly a lipofuscin signal from the retinal pigment epithelium, retinal diagnosis is now much more sophisticated, therapy can be better targeted to an individual patient's needs and clinical trials can use area of loss of autofluorescence as an outcome measure. Certain inherited retinal disorders have distinctive patterns of altered fluorescence and ageing changes can be followed with much greater precision. A global industry has built up around the devices required to image retinal autofluorescence safely.
A programme of methodological research undertaken by the University of York has shaped the economic evaluation methods used by the National Institute for Health and Care Excellence (NICE) since its inception, to assess the cost-effectiveness of healthcare interventions. Therefore the methods developed by York underpin many of the healthcare decisions by NICE on which new and existing interventions and programmes should be funded and used in the NHS. The methods used by NICE have also had a major influence on the approach taken to technology assessment internationally and so York's underpinning research has had wide impact beyond the UK.
Research at York has had a direct impact on national guidance about the use of health technologies in the NHS. It provided methods that are used to assess whether a technology is expected to be a cost-effective use of NHS resources, how uncertain this assessment is likely to be and whether additional evidence is sufficiently valuable to recommend further research to support its widespread use. It has had an impact on the technologies available in the NHS and the evidence available to support their use: improving patient outcomes; saving NHS resources and strengthening the evidence base for clinical practice. It gives an explicit signal and incentive to manufacturers; informing development decisions and the type of evidence collected. It has had an international impact on how the adequacy of evidence is judged and research is prioritised; particularly in recent reforms in the United States (US) where the principles of this value of information (VOI) analysis are informing the prioritisation of $3.8bn for `comparative effectiveness research'. It has also informed the methods used in low and middle income countries, especially national agencies in health care systems in South East Asia and South America, as well as global funding bodies.